Longitudinal analysis of structural biomarkers for disease progression in intermediate age-related macular degeneration: a MACUSTAR study report.
Structural biomarkers indicate risk for iAMD progression and may differentiate eyes progressing to GA from eyes progressing to nAMD, and needs to be considered in clinical trial design.